by Damien Contou, Megan Fraissé, Olivier Pajot, Jo-Anna
Tirolien, Hervé Mentec and Gaëtan Plantefève
Critical Care volume 25,
Article number: 3 (2021)
As many countries in Europe, France faced a second wave
COVID-19 pandemic since September, 2020. During the first wave, intensivists
faced an unprecedented massive admission of patients with COVID-19 pneumonia
requiring invasive mechanical ventilation, sometimes leading to ICUs
saturation. They discovered the stereotypical course of this previously unknown
disease with its own specificities including the need for deep sedation and
neuromuscular blockade, the increased risk of thrombotic and hemorrhagic events
[1, 2], and the prolonged duration of
mechanical ventilation [3] with high rate of delirium [4]. Importantly, several randomized
controlled trials conducted during this first wave highlighted the beneficial
effects of early administration of glucocorticoids for critically ill COVID-19
patients [5, 6].
One can legitimately assume that the experience gained
during the first wave may have contributed to a better management and outcome
among critically ill COVID-19 patients admitted during the second wave.
We therefore compared the characteristics and the outcome
between patients admitted to our 41-bed COVID-19 ICU for acute respiratory
failure due to COVID-19 (RT-PCR positive for SARS-CoV-2) during the first wave
(from March 13th to May 27th, 2020) and those admitted to our 18-bed ICU during
the second wave (from August 19th to December 7th, 2020).
COVID-19 patients without acute respiratory failure, those
transferred to other ICUs or still hospitalized in ICU were not included.
No comments:
Post a Comment